Does the media favor CORT or SUPN?

In the previous week, Corcept Therapeutics had 11 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 18 mentions for Corcept Therapeutics and 7 mentions for Supernus Pharmaceuticals. Corcept Therapeutics' average media sentiment score of 0.85 beat Supernus Pharmaceuticals' score of 0.80 indicating that Corcept Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Supernus Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SUPN or NKTR?

In the previous week, Supernus Pharmaceuticals and Supernus Pharmaceuticals both had 7 articles in the media. Supernus Pharmaceuticals' average media sentiment score of 0.80 beat Nektar Therapeutics' score of 0.67 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nektar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SUPN or PRGO?

In the previous week, Supernus Pharmaceuticals had 6 more articles in the media than Perrigo. MarketBeat recorded 7 mentions for Supernus Pharmaceuticals and 1 mentions for Perrigo. Supernus Pharmaceuticals' average media sentiment score of 0.80 beat Perrigo's score of 0.00 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Perrigo 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SUPN or PCRX?

In the previous week, Supernus Pharmaceuticals had 4 more articles in the media than Pacira BioSciences. MarketBeat recorded 7 mentions for Supernus Pharmaceuticals and 3 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.96 beat Supernus Pharmaceuticals' score of 0.80 indicating that Pacira BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacira BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OMER or SUPN?

In the previous week, Omeros and Omeros both had 7 articles in the media. Supernus Pharmaceuticals' average media sentiment score of 0.80 beat Omeros' score of 0.42 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Supernus Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Supernus Pharmaceuticals (SUPN) Competitors

$46.20 -0.99 (-2.10%)

As of 07/24/2026 04:00 PM Eastern

Compare

SUPN vs. CORT, NKTR, PRGO, PCRX, and OMER

Should you buy Supernus Pharmaceuticals stock or one of its competitors? MarketBeat compares Supernus Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Supernus Pharmaceuticals include Corcept Therapeutics (CORT), Nektar Therapeutics (NKTR), Perrigo (PRGO), Pacira BioSciences (PCRX), and Omeros (OMER). These companies are all part of the "pharmaceuticals" industry.

How does Supernus Pharmaceuticals compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

Corcept Therapeutics has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

Corcept Therapeutics presently has a consensus target price of $88.83, indicating a potential downside of 6.84%. Supernus Pharmaceuticals has a consensus target price of $62.83, indicating a potential upside of 36.00%. Given Supernus Pharmaceuticals' higher possible upside, analysts clearly believe Supernus Pharmaceuticals is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Corcept Therapeutics has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	13.44	$99.65M	$0.35	272.46
Supernus Pharmaceuticals	$718.95M	3.73	-$38.55M	-$0.51	N/A

93.6% of Corcept Therapeutics shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Corcept Therapeutics has a net margin of 6.14% compared to Supernus Pharmaceuticals' net margin of -3.74%. Supernus Pharmaceuticals' return on equity of 13.07% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.14%	7.40%	5.76%
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%

In the previous week, Corcept Therapeutics had 11 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 18 mentions for Corcept Therapeutics and 7 mentions for Supernus Pharmaceuticals. Corcept Therapeutics' average media sentiment score of 0.85 beat Supernus Pharmaceuticals' score of 0.80 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	10 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Supernus Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Corcept Therapeutics beats Supernus Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Nektar Therapeutics?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Nektar Therapeutics (NASDAQ:NKTR) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

In the previous week, Supernus Pharmaceuticals and Supernus Pharmaceuticals both had 7 articles in the media. Supernus Pharmaceuticals' average media sentiment score of 0.80 beat Nektar Therapeutics' score of 0.67 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nektar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Supernus Pharmaceuticals has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

Supernus Pharmaceuticals has higher revenue and earnings than Nektar Therapeutics. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.73	-$38.55M	-$0.51	N/A
Nektar Therapeutics	$55.63M	42.95	-$164.08M	-$8.42	N/A

Supernus Pharmaceuticals currently has a consensus price target of $62.83, suggesting a potential upside of 36.00%. Nektar Therapeutics has a consensus price target of $150.00, suggesting a potential upside of 112.10%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Nektar Therapeutics is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Supernus Pharmaceuticals has a net margin of -3.74% compared to Nektar Therapeutics' net margin of -284.18%. Supernus Pharmaceuticals' return on equity of 13.07% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%
Nektar Therapeutics	-284.18%	-85.40%	-39.99%

75.9% of Nektar Therapeutics shares are owned by institutional investors. 8.5% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Supernus Pharmaceuticals beats Nektar Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Perrigo?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Perrigo (NYSE:PRGO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

In the previous week, Supernus Pharmaceuticals had 6 more articles in the media than Perrigo. MarketBeat recorded 7 mentions for Supernus Pharmaceuticals and 1 mentions for Perrigo. Supernus Pharmaceuticals' average media sentiment score of 0.80 beat Perrigo's score of 0.00 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Perrigo	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Supernus Pharmaceuticals has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Perrigo has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

Supernus Pharmaceuticals presently has a consensus target price of $62.83, suggesting a potential upside of 36.00%. Perrigo has a consensus target price of $19.33, suggesting a potential upside of 91.86%. Given Perrigo's higher possible upside, analysts clearly believe Perrigo is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Supernus Pharmaceuticals has higher earnings, but lower revenue than Perrigo. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.73	-$38.55M	-$0.51	N/A
Perrigo	$4.18B	0.33	-$1.43B	-$13.10	N/A

95.9% of Perrigo shares are owned by institutional investors. 8.5% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 0.4% of Perrigo shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Supernus Pharmaceuticals has a net margin of -3.74% compared to Perrigo's net margin of -43.50%. Supernus Pharmaceuticals' return on equity of 13.07% beat Perrigo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%
Perrigo	-43.50%	9.96%	3.90%

Summary

Supernus Pharmaceuticals beats Perrigo on 12 of the 16 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Pacira BioSciences?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Pacira BioSciences (NASDAQ:PCRX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Pacira BioSciences has a net margin of 0.70% compared to Supernus Pharmaceuticals' net margin of -3.74%. Supernus Pharmaceuticals' return on equity of 13.07% beat Pacira BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%
Pacira BioSciences	0.70%	10.24%	5.47%

99.7% of Pacira BioSciences shares are owned by institutional investors. 8.5% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Supernus Pharmaceuticals had 4 more articles in the media than Pacira BioSciences. MarketBeat recorded 7 mentions for Supernus Pharmaceuticals and 3 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.96 beat Supernus Pharmaceuticals' score of 0.80 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacira BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Supernus Pharmaceuticals has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

Supernus Pharmaceuticals presently has a consensus target price of $62.83, indicating a potential upside of 36.00%. Pacira BioSciences has a consensus target price of $29.40, indicating a potential upside of 13.60%. Given Supernus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Supernus Pharmaceuticals is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Pacira BioSciences has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.73	-$38.55M	-$0.51	N/A
Pacira BioSciences	$726.41M	1.40	$7.03M	$0.12	215.67

Summary

Supernus Pharmaceuticals beats Pacira BioSciences on 9 of the 16 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Omeros?

Omeros (NASDAQ:OMER) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

In the previous week, Omeros and Omeros both had 7 articles in the media. Supernus Pharmaceuticals' average media sentiment score of 0.80 beat Omeros' score of 0.42 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Supernus Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

48.8% of Omeros shares are held by institutional investors. 10.5% of Omeros shares are held by company insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Omeros has higher earnings, but lower revenue than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	$9.89M	71.62	-$3.35M	$0.70	13.99
Supernus Pharmaceuticals	$718.95M	3.73	-$38.55M	-$0.51	N/A

Omeros has a beta of 2.55, suggesting that its stock price is 155% more volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

Omeros currently has a consensus price target of $38.00, indicating a potential upside of 288.15%. Supernus Pharmaceuticals has a consensus price target of $62.83, indicating a potential upside of 36.00%. Given Omeros' stronger consensus rating and higher probable upside, analysts plainly believe Omeros is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Omeros has a net margin of 0.00% compared to Supernus Pharmaceuticals' net margin of -3.74%. Supernus Pharmaceuticals' return on equity of 13.07% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%

Summary

Omeros beats Supernus Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

Get Supernus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SUPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SUPN vs. The Competition

Export

Metric	Supernus Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.74B	$5.34B	$6.87B	$12.26B
Dividend Yield	N/A	0.72%	2.67%	9.79%
P/E Ratio	-90.59	8.74	27.14	23.64
Price / Sales	3.73	25.89	517.06	88.99
Price / Cash	12.50	7.97	50.54	59.64
Price / Book	2.49	4.10	10.28	6.07
Net Income	-$38.55M	$99.67M	$3.60B	$331.99M
7 Day Performance	-3.83%	-5.64%	-1.27%	-0.63%
1 Month Performance	3.24%	-3.26%	-0.37%	-2.00%
1 Year Performance	37.58%	94.85%	18.30%	13.62%

Supernus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SUPN Supernus Pharmaceuticals	4.0405 of 5 stars	$46.20 -2.1%	$62.83 +36.0%	+40.6%	$2.74B	$718.95M	N/A	580	News Coverage Positive News Analyst Downgrade Short Interest Decrease
CORT Corcept Therapeutics	2.2484 of 5 stars	$94.73 +3.5%	$88.83 -6.2%	+41.1%	$10.19B	$761.41M	271.16	300	News Coverage Upcoming Earnings
NKTR Nektar Therapeutics	2.6178 of 5 stars	$66.09 +1.9%	$149.63 +126.4%	+187.7%	$2.23B	$55.23M	N/A	220	News Coverage Analyst Forecast Gap Up
PRGO Perrigo	3.9264 of 5 stars	$10.57 -0.2%	$19.33 +82.9%	-64.2%	$1.46B	$4.25B	N/A	8,100	Analyst Upgrade
PCRX Pacira BioSciences	2.0736 of 5 stars	$25.39 +0.2%	$29.40 +15.8%	+18.6%	$996.50M	$726.41M	211.05	720

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SUPN) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Supernus Pharmaceuticals (SUPN) Competitors

SUPN vs. CORT, NKTR, PRGO, PCRX, and OMER

How does Supernus Pharmaceuticals compare to Corcept Therapeutics?

Summary

How does Supernus Pharmaceuticals compare to Nektar Therapeutics?

Summary

How does Supernus Pharmaceuticals compare to Perrigo?

Summary

How does Supernus Pharmaceuticals compare to Pacira BioSciences?

Summary

How does Supernus Pharmaceuticals compare to Omeros?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SUPN vs. The Competition

Supernus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Supernus Pharmaceuticals (SUPN) Competitors

SUPN vs. CORT, NKTR, PRGO, PCRX, and OMER

How does Supernus Pharmaceuticals compare to Corcept Therapeutics?

Which has more volatility & risk, CORT or SUPN?

Do analysts recommend CORT or SUPN?

Which has preferable earnings and valuation, CORT or SUPN?

Do insiders & institutionals believe in CORT or SUPN?

Is CORT or SUPN more profitable?

Does the media favor CORT or SUPN?

Summary

How does Supernus Pharmaceuticals compare to Nektar Therapeutics?

Does the media refer more to SUPN or NKTR?

Which has more volatility & risk, SUPN or NKTR?

Which has higher earnings & valuation, SUPN or NKTR?

Do analysts rate SUPN or NKTR?

Is SUPN or NKTR more profitable?

Do insiders and institutionals hold more shares of SUPN or NKTR?

Summary

How does Supernus Pharmaceuticals compare to Perrigo?

Does the media refer more to SUPN or PRGO?

Which has more risk and volatility, SUPN or PRGO?

Do analysts rate SUPN or PRGO?

Which has preferable valuation & earnings, SUPN or PRGO?

Do insiders & institutionals hold more shares of SUPN or PRGO?

Is SUPN or PRGO more profitable?

Summary

How does Supernus Pharmaceuticals compare to Pacira BioSciences?

Is SUPN or PCRX more profitable?

Do insiders and institutionals believe in SUPN or PCRX?

Does the media refer more to SUPN or PCRX?

Which has more risk and volatility, SUPN or PCRX?

Do analysts prefer SUPN or PCRX?

Which has stronger earnings and valuation, SUPN or PCRX?

Summary

How does Supernus Pharmaceuticals compare to Omeros?

Does the media favor OMER or SUPN?

Do insiders & institutionals believe in OMER or SUPN?

Which has stronger valuation & earnings, OMER or SUPN?

Which has more risk and volatility, OMER or SUPN?

Do analysts recommend OMER or SUPN?

Is OMER or SUPN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SUPN vs. The Competition

Supernus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools